Quantcast

Latest Ticagrelor Stories

2014-07-02 08:24:16

LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: AstraZeneca PLC - Product Pipeline Review - 2014 http://www.reportbuyer.com/computing_electronics/manufacturing/astrazeneca_plc_product_pipeline_review_2013.html AstraZeneca PLC - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AstraZeneca PLC - Product Pipeline Review - 2014', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus....

2014-03-05 23:30:09

Dr. Dominick Angiolillo begins clinical study of rapid CYP2C19 genotyping in Jacksonville. Ottawa, Ontario (PRWEB) March 05, 2014 Spartan Bioscience today announced the start of a study of personalized medicine at the University of Florida. The Spartan RX CYP2C19 System is being used to test heart attack patients receiving cardiac stents. The study is entitled “A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function...

2013-10-15 12:56:38

Scientists from the University of Sheffield have discovered ground breaking clues as to how the pioneering heart drug ticagrelor might reduce the risk of dying following a heart attack, in comparison to previous standard treatments. The new findings, published in Platelets, show that ticagrelor may reduce the risk of dying as a result of a lung infection after suffering a heart attack compared to patients treated with the drug clopidogrel. The analysis, which was led by researchers from...

2012-08-29 07:53:39

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel. But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's...

2012-03-26 23:31:44

New research finds ongoing treatment with ticagrelor safe and effective in patients with acute coronary syndrome. Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall in patients with acute coronary syndromes (ACS), which are characterized by symptoms related to obstruction in coronary arteries, which supply blood to the...

2011-07-20 21:16:00

WILMINGTON, Del., July 20, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has approved BRILINTA(TM) (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/astrazeneca/50355/ BRILINTA,...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related